Health Sciences – PreveCeutical Medical, Inc.’s (OTCQB: PRVCF) (CSE: PREV) (FSE: 18H) ($PRVCF) interview with Stephen Van Deventer, Chairman/CEO.

Sep 28, 2023

PreveCeutical Medical, Inc.’s (OTCQB: PRVCF) (CSE: PREV) (FSE: 18H) ($PRVCF) (“PreveCeutical”) Chairman and CEO Stephen Van Deventer talks with New to The Street’s TV Host Jane King. PreveCeutical is a medical science company that develops innovative options for preventive and curative therapies using natural and organic compounds. The Company can synthesize molecular organic compounds through its proprietary technology and extensive peptide library to create preventative medical solutions. Using the technology, PreveCeutical developed a compound tested on mice, providing pre-clinical results on a non-addictive pain treatment more potent than opioids and morphine with no significant side effects. A pharmaceutical journal published a peer-review of the pre-clinical results. Stephen has a background in investment banking and was involved in the cannabis industry. He was involved with Aurora Cannabis Company and is passionate about finding organic and natural medical preventative solutions. The scientific team at PreveCeutical consists of doctors, PhDs, and engineers, all with impressive credentials in the pharmacology and pharmaceutical industries. With pre-clinical solid data, the team is moving forward on a clinical trial with the hopes of obtaining fast-track regulatory approvals in the US, Europe, and Australia for commercial distribution of a novel non-addictive pain management drug. The on-screen QR code is available during the show; download or visit PreveCeutical Medical, Inc. –

To make sure you never miss a video from New to the Street, click here to subscribe:

Follow New to the Street on Twitter:

Follow New to the Street on Facebook:

Follow New to the Street on Instagram:

Follow New to the Street on Rumble:

About New to the Street:

Subscribe to our Mailing List: